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The aim of the present study was to develop a transdermal system for controlled delivery of melatonin combining
three strategies: nanoencapsulation of melatonin, drying of melatonin-loaded nanocapsules, and incorporation of
nanocapsules in a hydrophilic gel. Nanocapsules were prepared by interfacial deposition of the polymer and were
spray-dried using water-soluble excipients. In vitro drug release profiles were evaluated by the dialysis bag method,
and skin permeation studies were carried out using Franz cells with porcine skin as the membrane. The use of 10%
(w/v) water-soluble excipients (lactose or maltodextrin) as spray-drying adjuvants furnished redispersible powders
(redispersibility index approximately 1.0) suitable for incorporation into hydrogels. All formulations showed a better
controlled in vitro release of melatonin compared with the melatonin solution. The best controlled release results
were achieved with hydrogels prepared with dried nanocapsules (hydrogels > redispersed dried
nanocapsules > nanocapsule suspension >melatonin solution). The skin permeation studies demonstrated a
significant modulation of the transdermal melatonin permeation for hydrogels prepared with redispersible
nanocapsules. In this way, the additive effect of the different approaches used in this study (nanoencapsulation,
spray-drying, and preparation of semisolid dosage forms) allows not only the control of melatonin release, but also
transdermal permeation.
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Melatonin (N-acetyl-5-methoxytryptamine) is a hor-
mone secreted by the pineal gland of mammals at night-
time, and it is involved in the regulation of the
sleep-wake cycle as well as in several biological func-
tions, including the regulation of mood, the control of
seasonal reproduction, and the circadian rhythm, in ani-
mals and humans. The administration of dosage forms
containing exogenous melatonin has been used to treat
circadian rhythm disorders such as jet lag and insomnia
[1]. Besides being a potent antioxidant, melatonin is a
free scavenger [1,2]; it protects against lipid peroxidation
in several models [3] and against oxidative stress in* Correspondence: ruy.beck@ufrgs.br
1Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade
Federal do Rio Grande do Sul, Av. 2752, Porto Alegre, CEP 90610-000, Brazil
Full list of author information is available at the end of the article
© 2012 Hoffmeister et al.; licensee Springer. Th
Commons Attribution License (http://creativeco
reproduction in any medium, provided the origsome neurodegenerative diseases such as Alzheimer's
disease [1,4]. Furthermore, it protects against ischemia/
reperfusion injury [5] and has antitumor activity [6].
Melatonin has a very short half-life and low and vari-
able oral bioavailability presumably due to variable
degrees of absorption and/or an extensive metabolism
by the liver [7,8]. Furthermore, melatonin is a poorly
water-soluble substance and has slow dissolution charac-
teristics [9]. Hence, melatonin is not a good candidate
for conventional oral immediate-release dosage forms
[8]. Thus, melatonin-sustained release formulations
have been developed for oral [8-14], intranasal [15],
transdermal [16-18], and transmucosal [18,19] adminis-
trations. Modified release tablets containing melatonin,
including β-cyclodextrin [9], microparticles [8,13,15],
hydroxypropylmethylcellulose matrix tablets [7], and
lecithin/chitosan nanoparticles [19], have been alsois is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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melatonin could be a very attractive alternative resulting
in sustained drug plasma levels that can be tailored
to the normal physiological range and avoid the first
pass effect [16]. Additionally, transdermal delivery could
overcome the low oral bioavailability of melatonin [20].
In this context, the skin protecting and non-irritant na-
ture of melatonin supports its candidature for transder-
mal delivery [17].
Over the past few decades, there has been considerable
interest in studying polymeric nanostructures as effective
drug delivery devices. Nanocapsules are vesicular sys-
tems composed of an oil-filled cavity surrounded by a
polymeric wall presenting narrow particle size distribu-
tion, and they are stabilized by surfactants at the par-
ticle/water interface [21-23]. In nanocapsules (<1 μm),
the drug can be dissolved, entrapped, encapsulated, and/
or adsorbed or attached to the polymeric particles
[21,22]. Despite the huge variety of promising applica-
tions of polymeric nanocapsules, in the area of transder-
mal delivery, these carriers have not yet been explored.
This via is advantageous because it is minimally invasive,
therefore avoids pain and risk of infections.
Previous studies have demonstrated that melatonin-
loaded EudragitW S100 nanocapsule suspensions were able
to improve the antioxidant effect of melatonin in both
in vitro and in vivo experiments [24,25]. In some cases,
these aqueous suspensions present limited physicochem-
ical stability under storage due to the possibility of particle
aggregation [26], the degradation of components such as
the polymer [27-29] or drug leakage [29-31]. Freeze-
drying [23,29] and spray-drying techniques [32,33] have
been reported as alternatives to improve the stability of
nanoparticle suspensions by means of their conversion
into powders. Spray-dried powders containing melatonin-
loaded EudragitW S100 nanocapsules were prepared using
silicon dioxide as drying adjuvants, showing a controlled
drug release profile in comparison with the pure drug
[34]. In addition, redispersible drug-free spray-dried poly
(E-caprolactone)-nanocapsules were developed using lac-
tose as the excipient [35].
Although the results of previous studies have demon-
strated the feasibility of preparing redispersible dried
polymeric nanocapsules, there is a lack of information in
the literature on the use of these powders for the devel-
opment of nanomedicines or nanocosmetics as final
dosage forms. In this context, the aim of this study was
to control the in vitro transdermal delivery of melatonin
by means of a strategy based on hydrogel formulations
containing spray-dried melatonin-loaded nanocapsules.
We hypothesized that the nanocarriers dried with the
aid of a water-soluble excipient and incorporated into
the semisolid formulation could modulate the transder-
mal delivery of melatonin.Methods
Materials
Melatonin was obtained from Acros Organics (Geel,
Belgium). Poly(methacrylic acid-co-methyl methacrylate)
(Eudragit S100W) was supplied by Almapal (São Paulo,
Brazil). The caprylic/capric triglyceride mixture was
obtained from Brasquim (Porto Alegre, Brazil). Sorbitan
monooleate (Span 80W), polysorbate 80 and triethanola-
mine were acquired from Delaware (Porto Alegre,
Brazil). Carbopol 940W was obtained from BF Goodrich
(Charlotte, NC, USA). Lactose and maltodextrin were
purchase from Henrifarma (São Paulo, Brazil) and
Roquette (Lestrem, France), respectively. All other che-
micals and solvents were of pharmaceutical grade and
used as received.
Preparation and characterization of nanocapsule
suspensions
Melatonin-loaded polymeric nanocapsules (NC) were pre-
pared (n=3) by interfacial deposition of the preformed
polymer according to the method described by Fessi and
co-workers [36]. The organic phase consisted of melatonin
(0.0125 g), caprylic/capric triglyceride mixture (0.8 mL),
Eudragit S100W (0.25 g), and Span 80W (0.1915 g) in acet-
one. This lipophilic solution was poured into a hydrophilic
phase containing polysorbate 80 (0.1915 g). Acetone was
removed, and the suspensions were concentrated by evap-
oration under reduced pressure to obtain a final volume of
25 mL (0.5 mg mL−1 of melatonin) [24].
The mean size and polydispersity of the nanocapsules
were determined at 25 ± 2°C by photon correlation spec-
troscopy (Zetasizer Nano ZEN3600, Malvern, UK). Sus-
pensions were diluted 500-fold in MilliQW water
(Millipore Co., Billerica, MA, USA). Zeta potential was
measured by an eletrophoretic technique, using the same
equipment. For these measurements, the suspensions
were diluted (1:500) with 10 mM NaCl aqueous solution.
The pH measurements were carried out directly in the
samples using a Micronal B474 potentiometer (Micronal,
São Paulo, Brazil).
The melatonin content of the nanocapsules was deter-
mined after their dissolution in acetonitrile and assayed
by high-performance liquid chromatography (HPLC)
[24]. The system consisted of an SPD-10A Shimadzu
detector, LC-10 AD Shimadzu pump, SIL-10A Shimadzu
injector (Shimadzu Corporation, Nakagyo-ku, Kyoto,
Japan), and LichrospherW RP-18 column provided by
Merck (Darmstadt, Germany). The mobile phase con-
sisted of acetonitrile/water (55:45, v/v) at a flow rate of
0.7 mL min−1. Melatonin was detected at 229 nm. The
encapsulation efficiency (percentage) was calculated by
difference between the total content and free melatonin
concentration in the nanocapsule suspension. The free
melatonin concentration was determined using the
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KDa, Millipore) [24].
Preparation and characterization of spray-dried polymeric
nanocapsules
Spray-dried melatonin-loaded nanocapsules were pre-
pared (n= 3) using an MSDW 1.0 spray dryer (Labmaq,
São Paulo, Brazil). Lactose and maltodextrin at 10%
(w/v) were evaluated individually as drying adjuvants.
The drying adjuvant was added to the nanocapsule sus-
pension under magnetic stirring. The stirring was main-
taining for 10 min before the formulation was fed into
the spray dryer. A two-fluid nozzle with a cap orifice
diameter of 0.7 mm and a co-current flow was used. The
inlet temperature in the drying chamber was maintained
at 150 ± 10°C, and the feeding rate was set at 0.3 L/h
[35]. Powders prepared with lactose and maltodextrin
were named as D-NC-L and D-NC-M, respectively.
The process yield (percentage) was calculated as the
ratio between the total weight of powder recovered in
the sample collector and the total dry mass of the com-
ponents used. The residual moisture content (percent-
age) of each spray-dried product was measured by Karl
Fischer titration in dry methanol (Titro Matric 1 S,
Crison Instruments, Barcelona, Spain). Measurements
were performed in triplicate. In order to determine the
melatonin content in the spray-dried powders, samples
were dispersed in methanol and kept under magnetic
stirring for 10 min. After centrifugation, melatonin was
assayed by HPLC according to the method described
above.
The size of the spray-dried powder particles was mea-
sured by laser diffractometry (Mastersizer 2000W,
Malvern, UK). Measure of the width of the distribution
of particle size (SPAN) values were used, and they were
calculated by (d0.9− d0.1)/d0.5 where d0.9, d0.5, and d0.1
are the particle diameters determined respectively at the
90th, 50th, and 10th percentile of undersized particles.
The deagglomeration profile of the dried particles was
evaluated as a function of time after their dispersion in
water (Hydro SM small volume sample dispersion unit,
Malvern, UK). Aliquots were analyzed every 5 min for
60 min. The aliquots acquired from 0 and 60 min were
also centrifuged, filtered (0.45 μm, Millipore), and ana-
lyzed by photon correlation spectroscopy (Zetasizer
Nano Series ZEN3600, Malvern, UK). Furthermore,
nanoparticle tracking analysis (NanoSight LM10 and
NTA 2.0 Analytical Software, NanoSight, Wiltshire, UK)
was also used as a tool to estimate the particle size dis-
tribution and to gain visual information. This experi-
ment was carried out using 0.5 mL of the diluted
samples (1:5,000 in milliQ water v/v) introduced into
the chamber by means of a syringe. The chamber was
placed on the optical microscope, and the particles wereilluminated by a laser diode (635-nm wavelength). The
video images of the Brownian motion of the individual
particles were obtained real time via CCD camera
and analyzed using the NTA 2.0 Analytical Software
(NanoSight, UK). In the nanoparticle tracking analysis
(NTA) method, the particle sizing system is based on
the scattering of light, where all visible particles in the
sample and each separate light scattering center are seen
as an individual particle during filming. Each video clip
was captured over 120 s. The automatic detection
threshold was enabled, and the maximum particle jump
was set at 10 in. the NTA software. The size values
obtained by NTA were used to evaluate the redispersion
efficiency (RE) of the spray-dried systems. The RE was
calculated using Equation 1, where values close to one




where dRP is the mean particle size of the redispersed
spray-dried powder and dS is the mean particle size of
the original nanocapsule suspension.
Morphological analysis of spray-dried powders was
carried out by scanning electron microscopy (JEOL
scanning microscope JSM-5800, Tokyo, Japan). Samples
were analyzed after they had been gold sputtered (JEOL
Jee 4B SVG IN, Tokyo, Japan), and the analysis was
performed at the Electron Microscopy Center of the
Federal University of Rio Grande de Sul State (Centro de
Microscopia Eletrônica - UFRGS).
Preparation and characterization of hydrophilic gels
Hydrogels were prepared using 0.5% of Carbopol 940W,
0.2% of diazolinidyl urea, and triethanolamine. Four differ-
ent formulations were prepared: (a) a hydrogel prepared
by adding Carbopol 940W directly to the nanocapsule sus-
pension (G-NC), (b) a hydrogel prepared by adding the
spray-dried nanocapsules (prepared with lactose) to a pre-
formed hydrogel (G-NC-L), (c) a hydrogel prepared by
adding the spray-dried nanocapsules (prepared with
maltodextrin) to a preformed hydrogel (G-NC-M), and
(d) a hydrogel prepared by adding directly the melatonin
dispersed in water containing polysorbate 80 at 0.77% to
preformed hydrogels (G-M). All formulations were pre-
pared at a final concentration of 0.5 mg g−1 of melatonin.
Hydrogels containing redispersed spray-dried nanocap-
sules (G-NC-L and G-NC-M) were prepared by adding
1.57 g of powder in 10 g of each hydrogel previously pre-
pared, reaching a final concentration of 0.5 mg g−1 of
melatonin. The pH values of the gels were determined
using a potentiometer (Micronal B474, São Paulo, Brazil)
through the direct immersion of the electrode in semiso-
lids (n=3). The physical stability of the hydrogels was
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mulaction, L'Union, France). The samples were poured
into glass cells without any dilution and analyzed using
scan mode every 6 min for 20 h at room temperature.
In vitro drug release profiles
In vitro drug release profiles (n= 3) from all formulations
(nanocapsule suspensions, dried nanocapsules, and
hydrogels) were studied under sink conditions using a
cellulose dialysis bag (MWCO=12,000 to 14,000 Da,
Sigma-Aldrich Corporation, St. Louis, MO, USA). Nano-
capsule suspensions (10 mL) and the hydrogels (10 g)
were transferred directly to the dialysis bags, which were
placed in a beaker containing 150 mL of 5% polysorbate
80 aqueous solution (at 37°C) with slow magnetic stir-
ring. For the spray-dried nanocapsules, the powders
were previously redispersed in 10 mL of water. The ini-
tial concentration of melatonin in the dialysis bag was
0.5 mg mL−1 for all samples. Aliquots of 2 mL were
withdrawn periodically and replaced with the same vol-
ume of fresh medium. The concentration of melatonin
released at each time was determined by HPLC using a
validated methodology previously described [24]. Drug
release profiles were analyzed by model-dependent
methods (mono-exponential and bi-exponential models)
using the software MicroMath ScientistW (St. Louis,
MO, USA). The best model to describe the release pro-
file was selected based on the highest model selection
criterion (MSC) and the highest correlation coefficient
(r), as well as the best curve fitting.
In vitro skin permeation studies
The in vitro permeation experiments were performed
using Franz type diffusion cells and pig abdomen skin at
37°C. Pig skin was obtained from a local slaughterhouse.
The skin was cleaned to remove the hair and adipose tis-
sue and kept at −20°C until use. The thickness of the
skin piece (1.5 to 2 mm) was measured using a microm-
eter (Dial Thickness Gage, 2046 S, Mitutoyo Corpor-
ation, Kanagawa, Japan). The dermal side of the porcine
flank skin was exposed to the receptor fluid (5.0% (v/v)
polysorbate 80 aqueous solution), and the stratum cor-
neum was exposed to the air (non-occlusive conditions).
The effective permeation area was 16 cm2, and the vol-
ume of the receiver chamber was around 50 mL.
The hydrogels were applied and weighed in the donor
compartment (50 mg/cm2). The flux of melatonin from
the nanocapsules through the skin was calculated by de-
termining the drug concentration in the receptor
medium at predetermined times (2, 4, 6, 8, 12, and 24 h)
by liquid chromatography (as previously described).
Results represent the mean of six independent replicates
(n= 6). The cumulative amounts of melatonin per diffu-
sion area were calculated for each time point and plottedversus the sampling time points. Flux corresponds to the
slope calculated by the linear regression of these data
points.
Statistical analysis
All analyses were carried out in triplicate. Results are
expressed as the mean ± standard deviation. Parameters
of the mathematical modeling (k, A, α, B, and β) and the
data of in vitro melatonin permeation were statistically
evaluated using one-way analysis of variance at a signifi-
cance level of 5% (StatGraphics Plus 5.1, STATPOINT
TECHNOLOGIES, INC., Warrenton, VA, USA).
Results and discussion
Polymeric nanocapsule suspensions
The melatonin-loaded nanocapsule suspension revealed a
mean particle size of 186± 24 nm with a low polydisper-
sity index (0.16 ± 0.03) and a pH of 3.87± 0.14. The zeta
potential was negative (−11.2± 5.1 mV) because of the
negative surface charge density at the particle/water inter-
face as a consequence of the presence of oxygen atoms in
the polymer backbone [37,38]. Drug content in the final
nanocapsule suspension was 0.477± 0.003 mg ml−1 with
an encapsulation efficiency of 63± 2%. All these results are
in accordance with the method of preparation, drug and
materials used, as previously reported by our group [24].
Spray-dried polymeric nanocapsules
Nanocapsule suspensions were spray-dried using lactose
or maltodextrin. The process yields were of 52 ± 8% and
50 ± 6% for spray-dried formulations using lactose
(D-NC-L) or maltodextrin (D-NC-M), respectively. The
operational conditions of the spray-drying process were
appropriate for the drying of the nanocapsules, as
demonstrated by the low moisture content of the dried
formulations (1.1 ± 0.1% and 1.7 ± 0.3% for D-NC-L and
D-NC-M, respectively).
Melatonin content in the spray-dried nanocapsules
was 3.17 and 3.36 mg g−1, for D-NC-L and D-NC-M, re-
spectively, corresponding to a complete recovery of the
drug after the drying process (99% and 105%, respect-
ively). However, some previous reports have described
that a segregation of the drug/materials during the
spray-drying process can occur, depending on the raw
material [33] or the parameters of the process [39].
Scanning electron microscopy (SEM) analysis showed
that the morphologies of the adjuvants and the spray-
dried nanocapsules vary considerably (Figure 1). Dried
lactose showed large agglomerates (Figure 1a), while
the spray-dried nanocapsules (D-NC-L) demonstrated
rugged microagglomerates (Figure 1b). On the other
hand, dried maltodextrin displayed collapsed microbal-
loons (Figure 1c). Spray-dried nanocapsules (D-NC-M)
showed rugged spherical microagglomerates (Figure 1d)
Figure 1 Images obtained by SEM of powders. (a) Pure lactose, (b) dried nanocapsules using lactose (D-NC-L), (c) pure maltodextrin, and
(d) dried nanocapsules using maltodextrin (D-NC-M) at × 3,000.
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using lactose. At higher magnification (×40,000), nano-
capsules can be observed in both microagglomerates
(Figure 2).
Water-soluble adjuvants were selected to dry melatonin-
loaded nanocapsules in order to obtain high redispersion
efficiency. Samples of redispersed D-NC-L and D-NC-M
were analyzed by laser diffractometry. Particle size distri-
butions were determined based on equivalent sphere ap-
proximation after dispersing the powders in water (0 and
60 min). Particle size distribution profiles of redispersed
D-NC-L and D-NC-M were compared to that of the ori-
ginal nanocapsule suspension (Figure 3). Immediately after
dispersion, the D-NC-L had three main particle popula-
tions. After 60 min, the profile showed the disappearanceFigure 2 Images obtained by SEM of powders. (a) D-NC-L and (b) D-NCof the population corresponding to the higher particle size,
a decrease in the intermediary particle size population,
and an increase in the nanometric population. This nano-
metric population presented a profile similar to that of the
original nanocapsule suspension, verifying that the D-NC-
L system can be redispersed, reaching nanosize distribu-
tion. In the case of the D-NC-M powder, the profile
showed two micrometric populations immediately after
redispersion in water. After 60 min, the areas of these
populations decreased, and a nanometric population was
observed. Although a micrometric population can still be
observed, the nanoscopic population presented a profile
similar to that of the original nanocapsule suspension.
This result indicated that D-NC-M system can be partially
redispersible, reaching nanosize distribution.-M at × 40,000.
Figure 3 Particle size distribution. (a) NC and D-NC-L at 0 and 60 min, and (b) NC and D-NC-M at 0 and 60 min.
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the size of a particle and its volume, we also analyzed
the size distribution in terms of numbers of particles
(Figure 4). After 60 min, D-NC-L and D-NC-M pre-
sented similar particle size profiles as that of the original
suspension (NC). Thus, the contribution of the micro-
metric populations observed for both redispersed pow-
ders after 60 min can be considered negligible.
To fully characterize the nanoscopic population, for-
mulations were also analyzed by photon correlation
spectroscopy. D-NC-L and D-NC-M showed z-averaged
diameters of 192 ± 50 nm and 181 ± 27 nm with polydis-
persity indexes of 0.33 ± 0.03 and 0.25 ± 0.10, respect-
ively. In order to determine the redispersibility
efficiency, the values for the ratio between the meandiameter of D-NC-L or D-NC-M and the mean size of
the original nanocapsules were calculated. The results
obtained were close to unity (1.03 and 0.97 for D-NC-L
and D-NC-M, respectively), demonstrating that the
dehydration-rehydration process did not lead to signifi-
cant changes in the nanometric size of the systems, re-
gardless of the adjuvant added.
Besides photon correlation spectroscopy (PCS), a
new technique based on the particle diffusion was
used to confirm the redispersion efficiency by deter-
mining the recovery of the nanoscopic sizes after the
aqueous redispersion of the powders. NTA is based
on a microscopic view of the particles illuminated by
a laser diode. Different intensities of the scattered
light are indicative of different particle sizes as larger
Figure 4 Particle size distribution (as number of particles) after 60 min of aqueous redispersion. (NC, D-NC-L, and D-NC-M).
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ger luminous dots are observed [40,41]. On the other
hand, smaller particles move faster and over longer
distances with respect to larger particles [40]. The
particle size distributions of the original nanocapsule
suspension, D-NC-L, and D-NC-M were determined
by NTA after 0 and 60 min. Figure 5 presents the
particle size distributions and a video frame of each
sample. The melatonin-loaded nanocapsule suspension
had an average particle size of 249 nm with a SPAN
value of 0.75 (Figure 5a). Immediately after redisper-
sion of the powders in water, the D-NC-L had a
mean particle size of 228 nm with a SPAN value of
1.43 (Figure 5b). The presence of lactose as an adju-
vant probably led to the appearance of a few particles
with sizes between 600 and 900 nm. In the case of
D-NC-M, the mean particle size was 280 nm with a
SPAN value of 2.06 (Figure 5d), indicating a broader
distribution compared with D-NC-L. Thus, lactose as
an adjuvant furnished a powder that is presenting
better homogeneity immediately after redispersion in
water. After 60 min of dispersing the powders, D-
NC-L and D-NC-M showed average sizes of 261 and
277 nm with SPAN values of 1.43 and 1.44, respect-
ively (Figure 5c,e). D-NC-L and D-NC-M presented
similar particle size distributions after 0 and 60 min
compared to the nanocapsule suspension. The calcu-
lated redispersibility efficiencies were 0.92 and 1.05
(D-NC-L) and 1.12 and 1.11 (D-NC-M), respectively.
The results corroborate the findings obtained by PCS
analysis.Hydrogels containing spray-dried melatonin-loaded
nanocapsules
Melatonin-loaded nanocapsule suspensions and spray-
dried nanocapsules (D-NC-L and D-NC-M) were
incorporated into semisolid hydrogels (G-NC, G-NC-
L, and G-NC-M, respectively). Hydrogels were white
and bright with pH values being close to neutral for
G-NC-L (7.11 ± 0.02) and for G-NC-M (7.10 ± 0.01);
while for G-NC, a slightly acid pH was observed
(5.8 ± 0.04).
The physical stability of the hydrogels was deter-
mined by multiple light scattering (Figure 6). In each
graph, the left side corresponds to the bottom of the
glass cell, and the right corresponds to the top. As a
control, the nanocapsule suspension (NC) was also
studied (Figure 6a). This suspension showed a slight
increase in the backscattering at the top, associated
with the creaming phenomenon, which is a reversible
type of physical instability. After incorporating the
nanocapsule suspension into a hydrogel (G-NC), the
creaming disappeared because of the higher viscosity
of the hydrogel, which reduces the particle mobility
(Figure 6b). Regarding G-NC-M, a decrease in the
relative backscattering at the center of the cell was
observed (Figure 6d), indicating a decrease in particle
size as a function of time. On the other hand, no
changes were observed in the analysis of G-NC-L
(Figure 6c), indicating a better physical stability com-
pared with G-NC-M. All variations in the relative
backscattering were lower than 5%, demonstrating a
good physical stability of formulations.
Figure 5 Particle size distribution (nanometers) (left) and sample video frame (right) obtained from NTA. (a) Original NC; (b) redispersed
D-NC-L at time 0; (c) redispersed D-NC-L after 60 min; (d) redispersed D-NC-M at time 0; and (e) redispersed D-NC-M after 60 min.
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Figure 6 Backscattering profiles of formulations. (a) NC, (b) G-NC, (c) G-NC-M, and (d) G-NC-L.
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The melatonin release from the nanocapsules was 90%
after 480 min, while the diffusion of the drug from the
solution reached 100% in 240 min (Figure 7a). The in-
corporation of either melatonin in solution or the
melatonin-loaded nanocapsule suspension in hydrogels
(G-M or G-NC, respectively) caused a decrease in the
melatonin released within these time intervals (61% and
63%, respectively) as well as in the standard deviations
(Figure 7b). These differences can be explained by the
higher viscosity of the gels compared with the liquid for-
mulations (NC and melatonin solution). Regarding the
spray-dried powders, after 480 min D-NC-L and D-NC-
M released 60% and 47%, respectively (Figure 7c), and
G-NC-L and G-NC-M released 47% and 42%, respect-
ively (Figure 7d). The release behavior of the hydrogels
compared to the powders and the liquid formulations is a
consequence of three contributions: (a) nanoencapsulation
of melatonin, (b) microagglomeration of nanocapsules in
the presence of the drying adjuvant, and (c) incorporation
in a semisolid vehicle (CarbopolW hydrogel).
The release profiles of NC, D-NC-L, D-NC-M, and
their respective hydrogels, G-NC, G-NC-L, and G-NC-
M, were modeled using the mono- or bi-exponential
model. The model that best fitted the experimental data
was selected based on the highest correlation coefficient(r), highest MSC, and the best curve fitting. Thus, the
bi-exponential was the best model to describe the release
profile for all formulations, with correlation coefficients
higher than 0.99 (Table 1). The kinetic parameters A
were higher than 0.70 for NC, D-NC-L, and D-NC-M,
suggesting that melatonin release was driven by a burst
effect. Release rates of the burst and sustained phases
(k1 and k2) calculated for the dried formulations were
lower than that obtained for the nanocapsule suspension
(NC). The results indicated that melatonin release from
the powders was slower than from the liquid dosage
forms. Additionally, the hydrogels (G-NC, G-NC-L, G-
NC-M) showed kinetic parameters B that are higher
than 0.70 (Table 1). Therefore, melatonin was mostly
released in the second phase, indicating a sustained drug
release. Thus, the addition of these formulations in
semisolid vehicles reduced the burst release of mela-
tonin, leading to prolonged release over time.
In vitro permeation studies
The skin permeation of melatonin from hydrogels (G-M,
G-NC, G-NC-L, and G-NC-M) was studied using Franz
cells with porcine skin as the membrane. Melatonin per-
meated into the receptor compartment was measured at
different time intervals (2 to 24 h; Figure 8). After 2 and
24 h, 25% and 100% of the melatonin from G-M
Figure 7 Profiles of melatonin release. These profiles are from (a) nanocapsule suspension in comparison to the melatonin solution, (b)
hydrogels (G-M or G-NC), (c) spray-dried powders (D-NC-L and D-NC-M), and (d) hydrogels prepared with spray-dried powders (G-NC-L and
G-NC-M).
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these values were 20% and 75%, respectively. No statis-
tical differences (p > 0.05) in the permeated melatonin
were observed in comparing G-NC and G-M for up to
12 h of the experiment. On the other hand, after 24 h,Table 1 Calculated release parameters of different
formulations containing melatonin-loaded nanocapsules,
according to the bi-exponential model
Formulation Parameter
A B k1 (min
−1) k2 (min
−1)
NC 0.88 ± 0.10 0.15 ± 0.11 0.0073 ± 0.0005 0.0017 ± 0.0011
D-NC-L 0.80 ± 0.02 0.28 ± 0.00 0.0058 ± 0.0002 0.0003 ± 0.0000
D-NC-M 0.78 ± 0.01 0.24 ± 0.02 0.0043 ± 0.0004 0.0004 ± 0.0001
G-NC 0.27 ± 0.04 0.72 ±0.04 0.0120 ± 0.0011 0.0016 ± 0.0001
G-NC-L 0.16 ±0.01 0.84 ± 0.00 0.1647 ± 0.0012 0.0012 ± 0.0000
G-NC-M 0.21 ± 0.10 0.74 ± 0.01 0.0072 ± 0.0002 0.0008 ± 0.0000the melatonin permeation was lower for G-NC com-
pared with that of G-M (p ≤ 0.05), showing the influence
of nanoencapsulation on the permeation. In addition, a
lower drug flux was observed for G-NC compared with
G-M (0.014 ± 0.002 μg cm−2 h−1 and 0.018 ± 0.002 μg cm
−2 h−1, respectively; p ≤ 0.05). Formulations containing
spray-dried powders showed lower amounts of perme-
ated melatonin for all time periods (20% and 15% of
melatonin for G-NC-L and G-NC-M, respectively after
4 h) compared with those of G-M or G-NC (p ≤ 0.05),
regardless of the type of the drying adjuvant. This result
may be explained by the higher control of mela-
tonin release from such formulations compared to the
melatonin-loaded nanocapsules due to the presence of
lactose or maltodextrin. Furthermore, lower drug fluxes
were observed forG-NC-L and G-NC-M (0.011 ± 0.002
and 0.013 ± 0.002 ug.cm-2.h-1) compared with the hydro-
gel prepared with non-encapsulated melatonin (G-M,
Figure 8 In vitro permeation profiles of melatonin from hydrogels. G-NC, original nanocapsules; G-NC-L and G-NC-M, dried nanocapsules;
and G-M, non-encapsulated melatonin (*significance, p≤ 0.05).
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drug fluxes from G-NC-L and G-NC-M with those from
G-NC, no statistical differences were observed. The
presence of lactose or maltodextrin caused a delayed
permeation of melatonin across the skin as observed in
Figure 8 (after 2 and 4 h of experiment). The influence
on these results of the rheological properties of the
hydrogels in the presence of these adjuvants should be
evaluated in further studies.
In general, the results of the permeation study corrob-
orate those obtained in the drug release studies, showing
lower melatonin release/skin permeation for the hydro-
gels prepared with the spray-dried nanocapsules as well
as the synergistic effect of the strategies employed in this
study (nanoencapsulation, spray-drying, and preparation
of semisolid dosage forms). In addition, with a view to
industrial production, spray-dried powders present the
advantages of being less susceptible to microbiological
contamination and more appropriate for storage and
transport.
Conclusions
Redispersible spray-dried melatonin-loaded nanocap-
sules were prepared using water-soluble excipients as
drying adjuvants (lactose or maltodextrin). Different
techniques showed the redispersion efficiency of spray-
dried nanocapsules. Laser diffraction, photon correlation
spectroscopy, and nanoparticle tracking analysis showed
similar results. The hydrogels prepared with melatonin-
loaded nanocapsules were able to control the release rate
of melatonin as well as to delay its permeation acrossthe pig skin. An additive effect of the nanoencapsulation,
spray-drying, and incorporation in semisolid dosage
forms explains the better control of the transdermal de-
livery of melatonin. This study represents a promising
strategy for the use of spray-dried nanocapsules in the
development of semisolid dosage forms for transdermal-
controlled delivery nanomedicines.
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